November 26, 2019 07:18 AM ESTUpdated 11:58 AM
R&D

Aca­di­a's sweep­ing hunt for bet­ter Nu­plazid da­ta bags mixed re­sults for schiz­o­phre­nia

Jason Mast

Editor

Five months af­ter their lead drug failed to treat schiz­o­phre­nia in a Phase III tri­al, Aca­dia is tout­ing just-bare­ly sig­nif­i­cant da­ta that sug­gest it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times